CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

All Clinical Trials for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00649233 ↗	Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg	Completed	Mylan Pharmaceuticals	Phase 1	2003-01-01	The objective of this study was to investigate the bioequivalence of Mylan metoprolol tartrate/hydrochlorothiazide 100/50 mg tablets to Novartis Lopressor HCT® 100/50 mg tablets following a single, oral 100/50 mg (1 x 100/50 mg) dose administration under fed conditions.
NCT00649688 ↗	Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg	Completed	Mylan Pharmaceuticals	Phase 1	2003-01-01	The objective of this study was to investigate the bioequivalence of Mylan metoprolol tartrate/hydrochlorothiazide 100/50 mg tablets to Novartis Lopressor HCT® 100/50 mg tablets following a single, oral 100/50 mg (1 x 100/50 mg) dose administration under fasting conditions.

Clinical Trial Conditions for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

Condition Name

Condition Name for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Intervention	Trials
Healthy	2
Hypertension	1

Condition MeSH

Condition MeSH for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Intervention	Trials
Pure Autonomic Failure	1
Hypertension	1

Clinical Trial Locations for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

Trials by Country

Trials by Country for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Location	Trials
United States	3

Trials by US State

Trials by US State for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Location	Trials
North Dakota	2
Tennessee	1

Clinical Trial Progress for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

Clinical Trial Phase

Clinical Trial Phase for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Clinical Trial Phase	Trials
Phase 1	3

Clinical Trial Status

Clinical Trial Status for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

Sponsor Name

Sponsor Name for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Sponsor	Trials
Mylan Pharmaceuticals	2
Vanderbilt University	1
Vanderbilt University Medical Center	1

Sponsor Type

Sponsor Type for HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE
Sponsor	Trials
Other	2
Industry	2

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE Market Analysis and Financial Projection

Last updated: May 4, 2026

Hydrochlorothiazide + Metoprolol Tartrate: Clinical-Trial Activity, Market Positioning, and Projection

What does the clinical-trials landscape show for hydrochlorothiazide plus metoprolol tartrate?

Hydrochlorothiazide (HCTZ) and metoprolol tartrate are off-patent, widely used antihypertensive agents that are commonly combined in clinical practice. Public trial activity is dominated by (1) investigator-initiated studies comparing antihypertensive regimens, (2) cardiovascular outcomes trials where beta-blockers and thiazides are used as background standard of care, and (3) bioequivalence and formulation work for generic fixed-dose combinations rather than new-molecule development.

Trial types that drive current activity

Across registries, trial-related activity for this drug set typically falls into these buckets:

Trial bucket	Typical objective	Typical enrollment size	Regulatory driver
Comparative effectiveness	Compare BP control, adherence, or tolerability vs alternative regimens	100 to 2,000	Academic and health-system
Safety in subpopulations	Evaluate electrolyte changes, bradycardia/fatigue, metabolic effects	100 to 1,500	Pharmacovigilance-linked studies
Fixed-dose combination (FDC) BE	Establish pharmacokinetic equivalence for generic products	20 to 200	Generic approvals
Observational registry-linked studies	Post-authorization outcomes in real-world settings	1,000 to 100,000	Health data networks

What is the practical implication for “update”

Because both actives are established and generics dominate, “clinical trials update” for this specific pairing usually means:

• Ongoing BE studies for new generic FDC entries.
• Ongoing comparative or safety studies that treat HCTZ and metoprolol as components of standard treatment rather than investigational therapies.

No new mechanism or late-stage (Phase 2/3) “program” structure is typically visible for the combination itself, which limits the value of searching for a single, clean development pipeline narrative.

How is the market positioned for this combination?

What the combination is used for

HCTZ plus metoprolol tartrate addresses hypertension through complementary mechanisms:

• HCTZ lowers BP by reducing sodium and water reabsorption (thiazide diuretic class).
• Metoprolol tartrate reduces BP by beta-1 selective adrenergic blockade (beta-blocker class).

In practice, this combination targets patients who require multi-drug BP control or who have comorbid cardiovascular indications where beta-blockers are already used.

Market context: off-patent economics

The most important market feature is that both components are long off-patent and widely available as generics. That shifts competitive dynamics toward:

• Price compression.
• Formulary access (managed care).
• Tolerability and adherence differentiators from FDC availability.
• Supply reliability and packaging/strength breadth.

Where demand typically comes from

Demand is driven by:

• Chronic hypertension prevalence and high persistence of therapy in older adults.
• Cardiovascular comorbidity cohorts where beta-blocker use is stable.
• Clinician preference for low-cost, guideline-consistent regimens.

Competitive set

For product-level competition, the relevant comparators are other beta-blocker-based combinations and thiazide combinations, including:

• Other thiazide combinations (with ACE inhibitors, ARBs, or other beta-blockers).
• Beta-blocker plus thiazide fixed doses from multiple generic manufacturers.
• Monotherapy substitution where payers incentivize single-agent step therapy.

What market projection is realistic given drug class dynamics?

Base-case market logic for projection

For off-patent fixed-dose combinations, projections are usually determined by three levers:

1. Volume continuity: Hypertension treatment base persists.
2. Unit price erosion: Ongoing generic competition reduces net price over time.
3. Formulary/brand migration: Patients and prescribers shift based on side effects, dosing convenience, and reimbursement.

Projection framework (scenario ranges)

Because the combination is mature and generic-led, projections typically use a range rather than a single-point forecast. A practical scenario set is:

Horizon	Base case (most likely)	Upside scenario	Downside scenario
1 to 3 years	Flat to low-single-digit growth in units, mid-to-high single-digit decline in unit price	Faster FDC uptake in formularies; slower price erosion	Greater substitution to other combination classes or single-pill regimens
3 to 7 years	Slight net revenue growth or flat-to-low growth driven by volume offsetting price	Continued preference for beta-blocker + thiazide in certain comorbidity groups; stable payer coverage	Intensified price pressure; switching toward newer low-cost combinations

Key numeric drivers you should model

For an investment-grade projection, the metrics that usually control outcomes for this class are:

Driver	What moves it	Typical direction
Net price	Generic entry, rebate pressure	Down
Prescribing share	Guideline adherence by comorbidity	Mixed to stable
Persistence/adherence	FDC availability	Up versus fragmented dosing
Switch rate	Side effects (electrolyte, bradycardia) and tolerability	Up when adverse events accumulate
Competitive substitution	Other cheap combinations and “once-daily convenience”	Depends on formulary

What is the clinical and safety footprint that affects demand?

Physiologic constraints

For HCTZ + metoprolol tartrate combinations, the main tolerability considerations that influence continuation are:

• HCTZ-associated risks: hypokalemia, hyponatremia, increased uric acid, glucose changes.
• Metoprolol-associated risks: bradycardia, fatigue, hypotension, exercise intolerance.

These do not eliminate the regimen’s use, but they do shape switching and persistence, especially in older and comorbid populations.

Real-world consequence for market

Regimens that maintain tolerability and adherence in chronic use tend to sustain volume. When side effects trigger dose adjustments or switching, unit volume can lag prevalence growth.

What should be monitored for the next 12 to 24 months?

Signal categories

For both developers (generic/formulation) and investors (market sizing), monitor:

1. New fixed-dose entries: Strength breadth expansion, packaging changes, and additional generic approvals that increase supply.
2. Formulary actions: Managed care changes that favor or disfavor beta-blocker + thiazide regimens.
3. Comparative evidence updates: Trials that evaluate BP control targets, adherence, and discontinuation rates in routine care.
4. Safety signals in subpopulations: Data updates on electrolyte disturbances and bradycardia/hypotension outcomes.

Key takeaways

• Clinical activity for hydrochlorothiazide plus metoprolol tartrate is largely “mature-drug” activity: BE/formulation work and comparative or safety studies using the regimen as part of standard antihypertensive management.
• Market growth is constrained by off-patent economics, so projections should be modeled on unit volume plus continued net price erosion and formulary coverage stability.
• Demand persistence is supported by chronic hypertension prevalence and beta-blocker use in comorbid patients, while safety-driven switches (electrolytes, bradycardia) are the main counterforce.

FAQs

1) Are there any late-stage (Phase 2/3) development programs for the hydrochlorothiazide plus metoprolol tartrate combination?
Public trial activity is mainly BE/formulation and comparative effectiveness or safety studies rather than a new-molecule Phase 2/3 pipeline centered on the exact combination.

2) Why does the market not behave like a patent-protected cardiovascular blockbuster?
Both actives are off-patent and widely available as generics, so price compression and formulary access drive outcomes more than R&D differentiation.

3) What endpoints matter most for continued use of this regimen in real-world practice?
Discontinuation rates, BP control persistence, and tolerability (electrolytes for HCTZ, bradycardia and fatigue for metoprolol) are the metrics that typically correlate with switching.

4) What is the biggest driver of revenue for generic fixed-dose combinations in the next few years?
Net price and formulary positioning, with unit volume supported by chronic prevalence but tempered by substitution.

5) Does fixed-dose availability change adherence enough to affect market share?
In practice, FDCs can improve adherence versus separate dosing, which can stabilize persistence, but payers and clinicians still switch based on tolerability and regimen convenience.

---

References

[1] National Library of Medicine. ClinicalTrials.gov database. Accessed 2026-05-04. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. Drugs@FDA database. Accessed 2026-05-04. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization. ATC classification system. Accessed 2026-05-04. https://www.who.int/tools/atc-ddd-toolkit/atc-classification/
[4] American Heart Association. Hypertension guideline resources and BP management updates. Accessed 2026-05-04. https://www.heart.org/